What Is Lipoprotein(a) and Why It Matters
Lipoprotein(a), or Lp(a), is a cholesterol-like particle made in the liver. Unlike LDL or “bad” cholesterol, Lp(a) levels are mostly inherited. You can have high levels even with a healthy lifestyle.
Elevated Lp(a) is a strong, independent risk factor for atherosclerotic cardiovascular disease (ASCVD)—including heart attacks, strokes, and narrowing of arteries. Until recently, no medication specifically targeted Lp(a).
What This New Study Found
Researchers have tested a new treatment called lepodisiran, an investigational small interfering RNA therapy. It’s designed to block the liver from making Lp(a). The results are promising.
Study Overview
- 320 participants with high Lp(a) joined the trial. Average baseline Lp(a) was 254 nmol/L.
- They received one of five treatment plans, including placebo or different doses of lepodisiran given under the skin.
- The goal was to see how much Lp(a) levels dropped over time, especially between days 60 and 180.
Key Results
Lepodisiran lowered Lp(a) levels dramatically—and the effect lasted many months.
| Lepodisiran Dose | Lp(a) Reduction (Day 60–180) |
|---|---|
| 16 mg | 41% |
| 96 mg | 75% |
| 400 mg | 94% |
This reduction held up through day 360, especially in the highest dose group. That means a single shot may control Lp(a) for up to a year.
What About Side Effects?
Lepodisiran was generally well-tolerated:
- Serious adverse events occurred in 35 participants, but none were linked to lepodisiran.
- Mild injection-site reactions were reported in up to 12% of those receiving the highest dose.
Why Holistic, Individualized Care Matters
For those at risk of heart disease, managing cholesterol is just one part of the picture. High Lp(a) often coexists with other metabolic issues like insulin resistance, elevated ApoB, or early hypertension.
In our practice in Montgomery County, Maryland, we approach each patient from multiple perspectives:
- Advanced lipid panels (including Lp(a), ApoB, and LDL particle count)
- Coronary Calcium Score.
- Deep dive into family history
- Nutrition and lifestyle tailored to your metabolic blueprint
- Smart medication choices based on risk level and values
We focus on personalized care, not one-size-fits-all solutions.
Takeaway: A New Era for Lp(a) Treatment?
This study shows lepodisiran may become a game-changer in cardiovascular prevention—especially for those with genetically high Lp(a).
Although it’s not yet available for general use, it signals a future where we can target Lp(a) directly, safely, and for the long term.
If you’ve been told your Lp(a) is high, or you have a family history of early heart disease, this is the right time to take a thoughtful, strategic approach.
References:
Nissen SE, Ni W, Shen X, et al. Lepodisiran—a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025 Mar 30. DOI: 10.1056/NEJMoa2415818.
About Dr. Gerti Tashko, MD
Dr. Gerti Tashko, MD, is an endocrinologist in Montgomery County, Maryland. He is uniquely quadruple board-certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice delivers root-cause-focused metabolic and endocrine care, available virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to improve long-term health.
